Containing the active substance tirzepatide, the Mounjaro KwikPen is a leading-edge medical solution designed to manage blood sugar levels in adults with type 2 diabetes and aid in weight management. This easy-to-use pre-filled injection pen helps regulate appetite and reduce food cravings by promoting a feeling of fullness.
Mounjaro is not just a medication but a lifestyle change facilitator. It is prescribed for:
This innovative pen simplifies diabetes management and weight control with numerous benefits:
Starting with a dose of 2.5 mg once a week, the dosage can be adjusted based on therapeutic response but should only be modified under medical supervision. The pen allows for flexible administration, capable of being used at any time of the day, with or without meals.
While this medication is a powerful tool for managing diabetes and weight, it can have side effects, which may include nausea, diarrhea, and hypoglycemia. Most side effects are manageable and tend to decrease over time.
Before using this medication, discuss potential health risks with your healthcare provider. It should not be used if you are allergic to tirzepatide or during pregnancy. Monitoring for symptoms of pancreatitis is crucial due to severe possible complications.
Store the pen in a refrigerator, but it can be kept at room temperature under 30°C for up to 30 days. Do not freeze, and discard if the medication becomes cloudy or discolored.
Reporting side effects is essential for gathering more information about the safety of this medication. Side effects can be reported to your health provider or directly via the MHRA Yellow Card Scheme.
privateprescriptions@
pharmaease.co.uk
This website is operated by Nationwide Healthcare Solutions Limted t/a Pharmaease. Registered in England, company number: 07278785. Registered office: 172 Willows Lane, Bolton, BL3 4BU. Registered with Information Comissioners Office, registration: ZA408214. Registered with the General Pharmaceutical Council, registration number: 9010200. Superintendent Pharmacist: Mr. Muhammad Rafiq, registration number: 2065278.